NCT00270452View on ClinicalTrials.gov

Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

December 22, 2005

Primary Completion Date

October 26, 2007

Study Completion Date

October 26, 2007

Conditions
Myelodysplastic Syndrome (MDS)
Interventions
DRUG

WT1 and PR1 Peptide Vaccine

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Heart, Lung, and Blood Institute (NHLBI)

NIH

NCT00270452 - Safety of Peptide Vaccination for Patients With Myelodysplastic Syndrome | Biotech Hunter | Biotech Hunter